GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) price target bumped up to $91.16, reported today by Vetr Inc.
- Updated: September 16, 2016
Stating a possible upside of 0.08%, Vetr Inc. bumped the target price of GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) to $91.
On 8/09/2016, Cantor Fitzgerald reported about GW Pharmaceuticals PLC- ADR(NASDAQ:GWPH) dropped the target price from $181.00 to $165.00 that indicated a possible upside of 0.76%.
Boasting a price of $84.38, GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH) traded 0.03% higher on the day. The last stock close is up 26.07% from the 200-day moving average, compared with the S&P 500 which has fallen -0.01% over the same time. GWPH has logged a 50-day moving average of $90.31 and 200-day moving average of $83.38. Volume of trade was was down over the average, with 435,460 shares of GWPH changing hands under the typical 626,595 shares.
See Graph Below:
GW Pharmaceuticals PLC- ADR has a one-year low of $35.83 and a one-year high of $114.63. GWPH’s market cap is currently $0.0.
A total of 8 firms have reported on the company. Two firms rate the stock a strong buy, five firms rate the stock a buy, 0 analysts rate the company a hold, 0 rate the company to underperform, and finally 0 analystsrate the stock as sell with an average target price of $139.75
About GW Pharmaceuticals PLC- ADR (NASDAQ:GWPH)
GW Pharmaceuticals plc is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The Company develops a portfolio of cannabinoid medicines, including Epidiolex, which is an oral medicine for the treatment of refractory childhood epilepsies. The Company operates through three segments: Commercial, Sativex Research and Development (Sativex R&D), and and Pipeline Research and Development. The Commercial segment distributes and sells the Company’s commercial products. The Sativex R&D segment seeks to maximize the potential of Sativex through the development of indications. The Sativex R&D segment focuses on the Phase III clinical development program of Sativex for use in the treatment of cancer pain. The Pipeline Research and Development segment seeks to develop cannabinoid medications other than Sativex across a range of therapeutic areas using the Company’s cannabinoid technology platform.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.